Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992741 | 0.84 | TDP1 (0.33) | TDP1TSHR | |
| SCHEMBL7199463 | 0.83 | — | — | |
| SCHEMBL6891499 | 0.77 | — | — | |
| SCHEMBL10530966 | 0.74 | TDP1 (0.35) | TDP1TSHR | |
| SCHEMBL602024 | 0.74 | TDP1 (0.35) | TDP1TSHR | |
| SCHEMBL6891504 | 0.74 | TDP1 (0.35) | TDP1TSHR | |
| SCHEMBL9341152 | 0.72 | HTT (0.33) | TSHR | |
| SCHEMBL1402719 | 0.69 | TDP1 (0.31) | TDP1TSHR | |
| SCHEMBL8328895 | 0.69 | TDP1 (0.38) | TDP1TSHR | |
| SCHEMBL1500492 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3074398-A | — | — | None | — | — | JP | disclosed |
| WO-2024127026-A1 | MEMBRANE FILTRATION-ASSISTED SOLUTION PHASE OLIGONUCLEOTIDE SYNTHESIS | Exactmer Limited (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230272382-A1 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | BANK OF AMERICA, N.A. | 2023-08-31 | — | — | US | disclosed |
| US-20230016929-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2023-01-19 | — | — | US | disclosed |
| EP-4114947-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | Alnylam Pharmaceuticals, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4055166-A2 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| WO-1996004295-A1 | 5'-DITHIO-MODIFIED OLIGONUCLEOTIDES | AMGEN INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0691980-A1 | 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES | STERLING WINTHROP INC (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5459243-A | Apparatus and processes for the large scale generation and transfer of diazomethane | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1994022892-A1 | 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES | STERLING WINTHROP INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5272077-A | Method for preparing a covalent conjugate of an oligonucleotide and an enzyme | EASTMAN KODAK COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| US-5254469-A | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures | EASTMAN KODAK COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5082780-A | OLIGONUCLEOTIDE-ENZYME CONJUGATE THAT CAN BE USED AS A PROBE IN HYBRIDIZATION ASSAYS AND POLYMERASE CHAIN REACTION PROCEDURES | EASTMAN KODAK COMPANY (US) | 1992-01-21 | — | — | US | disclosed |
| JP-H0374398-A | PHOSPHORAMIDITE COMPOUND AND METHOD FOR SYNTHESIZING OLIGORIBONUCLEOTIDE IN SOLID PHASE USING THE SAME | YUKI GOSEI KOGYO CO LTD | 1991-03-28 | — | — | JP | disclosed |
| EP-0417841-A2 | An oligonucleotide-enzyme conjugate and a method for its preparation | EASTMAN KODAK COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | TDP1 1238/4885TSHR 1783/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | TDP1 1238/4885TSHR 1783/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | TDP1 101/4885TSHR 510/4885 |
| US-20230016929-A1 | EXTRAHEPATIC DELIVERY | SLC10A1, FABP1, SLC67A1 | TDP1 2603/4885TSHR 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.